Pharmaceutical multinational AstraZeneca has suffered a shareholder revolt in which 39 % of investors voted against the company ’s earnings report for 2016 , including a £ 13 m ( $ 10 m ) package for its CEO , # ##riot . The company faced a similar revolt three years ago . However , new pay policy proposals were supported by 96 % of investors . Soriot ’s pay gap was particularly large last year because a long - term incentive plan paid out . AstraZeneca said that it had made changes to its long - term bonus plans and would continue its “ dialogue with investors ” .
Pharmaceutical multinational AstraZeneca has suffered a shareholder revolt in which 39% of investors voted against the group’s remuneration report for 2016, including a £13m ($16.8m) package for its CEO, Pascal Soriot. The company faced a similar revolt three years ago. However, new pay policy proposals were supported by 96% of investors. Soriot’s pay package was particularly large last year because a long-term incentive plan paid out. AstraZeneca said that it had made changes to its long-term bonus plans and would continue its “dialogue with shareholders”.